High-dose methotrexate-doxycycline interaction

Annals of Pharmacotherapy

Volumn 33, Issue 7-8, 1999, Pages 804-808

  Tortajada Ituren, Juan José ^a   Ordovás Baines, Juan Pablo ^b   Llopis Salvia, Pilar ^b   Victor Jimenez Torres N ^b  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b Hospital Universitario Dr Peset ^*

Author keywords

Doxycycline; Methotrexate

Indexed keywords

DOXYCYCLINE; METHOTREXATE;

ADOLESCENT; ARTICLE; CASE REPORT; COST BENEFIT ANALYSIS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INTOXICATION; DRUG MEGADOSE; DRUG MONITORING; EYE INFECTION; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0344549348     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18236     Document Type: Article

References (27)

1. Jaffe N, Patel SR, Benjamin RS. Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation. Hematol Oncol Clin North Am 1995;9: 825-40.
2. Goorin A, Strother D, Poplack D, Letvak LA, George M, Link M. Safety and efficacy of 1-leucovorin rescue following high-dose methotrexate for osteosarcoma. Med Pediatr Oncol 1995;24:362-7.
3. Ordovás JP, Ronchera CL, Rosique D, Jiménez NV. Iatrogenia por metotrexato iv a altas dosis. Ciencia Pharmacéutica 1991;1:85-91.
4. Thyss A, Milano G, Kubar J, Namer M, Schenider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1986;1:256-8.
5. Daly HM, Scott GL, Boyle J, Roberts CJ. Methotrexate toxicity precipitated by azapropazone. Br J Dermatol 1986;114:733-5.
6. Singh RR, Malaviya AN, Pandey JN, Guleria JS. Fatal interaction between methotrexate and naproxen (letter). Lancet 1986;1:1390.
7. Maiche AG. Acute renal failure due to concomitant action of methotrexate and indomethacin (letter). Lancet 1986;1:1390.
8. Cassano WF. Serious methotrexate toxicity caused by interaction with ibuprofen (letter). Am J Pediatr Hematol Oncol 1989;11:481-2.
9. Hernández T, Jiménez NV, Ronchera CL, Ordovás JP. Interacción farmacocinética entre metotrexato a altas dosis y dipirona. Rev Farmacol Clin Exp 1989;6:77-81.
10. Frenia ML, Long KS. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann Pharmacother 1992;26:234-7.
11. Dean R, Nachman J, Lorenzana AN. Possible methotrexate-mezlocillin interaction (letter). Am J Pediatr Hematol Oncol 1992;14:88-9.
12. Ronchera CL, Hernández T, Peris JE, Torres F, Granero L, Jiménez NV, et al. Pharmacokinetic interaction between high-dose methotrexate and amoxycillin. Ther Drug Monit 1993;15:375-9.
13. Yamamoto K, Sawada Y, Matsushita Y, Moriwaki K, Bessho F, Iga T. Delayed elimination of methotrexate associated with piperacillin administration. Ann Pharmacother 1997;31:1261-2.
14. Thomas MH, Gutterman LA. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. J Rheumatol 1986;13:440-1.
15. Thomas DR, Dover JS, Camp RD. Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole (letter). J Am Acad Dermatol 1987;17:1055-6.
16. Jeurissen ME, Boerbooms AM, van de Putte LB. Pancytopenia and methotrexate with trimethoprim-sulfamethoxazole (letter). Ann Intern Med 1989;111:261.
17. Turck M. Successful psoriasis treatment then sudden "cytotoxicity." Hosp Pract 1984;19:175-6.
18. Basin KS, Escalante A, Beardmore TD. Severe pancytopenia in a patient taking low dose methotrexate and probenecid. J Rheumatol 1991;18: 609-10.
19. Korstanje MJ, van Breda Vriesman CJ, van de Staak WJ. Cyclosporine and methotrexate: a dangerous combination. J Am Acad Dermatol 1990; 23:320-1.
20. Reid T, Yuen A, Catolico M, Carlson RW. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol 1993; 33:82-4.
21. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978;41:36-51.
22. Ertmann R, Landbeck G. Effect of oral cholestyramine on the elimination of high-dose methotrexate. J Cancer Res Clin Oncol 1985;110:48-50.
23. Evans WE, Pratt CB, Taylor H, Barker LF, Crom WR. Pharmacokinetic monitoring of high-dose methotrexate: early recognition of high-risk patients. Cancer Chemother Pharmacol 1979;3:161-6.
24. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet 1988;15:355-66.
25. Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 1978;3:1-13.
26. EuroQol Group. EuroQol: a new facility for the measurement of health related quality of life. Health Policy 1990;16:199-208.
27. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.